Investors are increasingly looking to biotechnology companies for potential breakthroughs and profitable returns, as the sector shows resilience and growth amid broader market volatility. Within this landscape, Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is capturing attention with its promising drug portfolio and financial performance.
Guggenheim Partners assumed coverage on Syndax Pharmaceuticals, citing strength after the second-quarter earnings. Syndax reported a second-quarter loss of 83 cents per share, narrower than the expected loss of $1.00, on revenue of $37.96 million, topping estimates of $26.78 million.
